Researchers at the Massachusetts Institute of Technology (MIT) have developed two new antibiotic candidates using generative artificial intelligence (AI) to combat drug-resistant bacteria, including gonorrhoea and methicillin-resistant Staphylococcus aureus (MRSA). The AI technology analyzed 36 million compounds, including many previously unknown molecules, to design these novel antibiotics, which have demonstrated effectiveness in laboratory tests and in vivo models. This approach leverages advances similar to those behind AI tools like ChatGPT and represents a promising step forward in addressing antimicrobial resistance. The research is a collaboration involving MIT, the Broad Institute, and the Wyss Institute. While still years away from clinical application, this development highlights the growing role of AI in drug discovery and medical science. Additional advances in AI-driven biomedical research include improved genome editing techniques for diseases such as sickle cell disease and enhanced CAR T cell therapies.